Taoxi Lin, master's degree, graduated from Nanjing University and Sun Yat sen University, guest professor of Huarui Lvyun Law School of China Behavioral Law Society, Teng Long student of China Enterprise Intellectual Property Institute, tutor of Powerful Intellectual Property Institute, director of Dongguan Patent Protection Association, director of Intellectual Property Center of State Key Laboratory of Anti infective New Drugs, and outstanding intellectual property worker of China National Intellectual Property Administration in 2016, Outstanding Intellectual Property Manager in China in 2017; Joined HEC Group in 2006 and currently serves as the Director of Intellectual Property; During my time working at HEC Group, the company's intellectual property business has made significant progress and development: nearly 2000 patent applications, over 300 PCT applications, and foreign applications, ranking first in China's pharmaceutical industry in terms of number of applications. Six of the first generic drugs in the United States are currently undergoing patent challenge litigation in the United States, ranking 21st in the entire industry on the US patent litigation ranking. Several subsidiaries of the group have been rated as national intellectual property demonstration and advantageous enterprises. As of the end of 2017, The operating patent pledge financing amount reaches over 5 billion yuan.